Header Logo

Connection

SALIM VIRANI to Hypolipidemic Agents

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Hypolipidemic Agents.
SALIM VIRANI
Connection Strength
4.576
Hypolipidemic Agents
  1. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Cardiovasc Drugs Ther. 2021 12; 35(6):1269-1279.
    View in: PubMed
    Score: 0.635
  2. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
    View in: PubMed
    Score: 0.596
  3. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.570
  4. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. Am J Cardiol. 2016 Sep 15; 118(6 Suppl):13A-8A.
    View in: PubMed
    Score: 0.480
  5. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.403
  6. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.387
  7. Implementation strategies to improve non-HDL-cholesterol goal attainment: current evidence and a conceptual framework for future directions. Tex Heart Inst J. 2012; 39(2):228-30.
    View in: PubMed
    Score: 0.347
  8. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011; 38(2):160-2.
    View in: PubMed
    Score: 0.323
  9. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.168
  10. Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs. 2020 Jun; 29(6):611-622.
    View in: PubMed
    Score: 0.155
  11. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel?Survey. J Am Heart Assoc. 2018 01 22; 7(2).
    View in: PubMed
    Score: 0.132
  12. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2015 Nov; 170(5):865-71.
    View in: PubMed
    Score: 0.111
  13. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.101
  14. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.084
  15. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep. 2007 Aug; 9(2):97-103.
    View in: PubMed
    Score: 0.064
  16. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.